On Oct 25, major Wall Street analysts update their ratings for $Alkermes (ALKS.US)$, with price targets ranging from $30 to $43.
Goldman Sachs analyst Chris Shibutani maintains with a buy rating, and adjusts the target price from $32 to $30.
TD Cowen analyst Joseph Thome maintains with a buy rating, and maintains the target price at $35.
Piper Sandler analyst David Amsellem maintains with a buy rating, and adjusts the target price from $38 to $37.
Cantor Fitzgerald analyst Charles Duncan maintains with a buy rating, and adjusts the target price from $48 to $43.
H.C. Wainwright analyst Douglas Tsao maintains with a hold rating, and maintains the target price at $37.
Furthermore, according to the comprehensive report, the opinions of $Alkermes (ALKS.US)$'s main analysts recently are as follows:
Alkermes' Q3 results reflected a mixed performance from its existing commercial portfolio, aligning broadly with expectations. The company is demonstrating a commitment to intensifying and concentrating its investments on ALKS-2680 and its orexin-2 receptor agonist pipeline, which may moderate short-term profitability. Nonetheless, there is optimism surrounding the long-term value generation prospects of ALKS-2680.
Here are the latest investment ratings and price targets for $Alkermes (ALKS.US)$ from 5 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間10月25日，多家華爾街大行更新了$阿爾凱默斯 (ALKS.US)$的評級，目標價介於30美元至43美元。
高盛集團分析師Chris Shibutani維持買入評級，並將目標價從32美元下調至30美元。
TD Cowen分析師Joseph Thome維持買入評級，維持目標價35美元。
派傑投資分析師David Amsellem維持買入評級，並將目標價從38美元下調至37美元。
坎托·菲茨杰拉德分析師Charles Duncan維持買入評級，並將目標價從48美元下調至43美元。
H.C. Wainwright分析師Douglas Tsao維持持有評級，維持目標價37美元。
此外，綜合報道，$阿爾凱默斯 (ALKS.US)$近期主要分析師觀點如下：
以下爲今日5位分析師對$阿爾凱默斯 (ALKS.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
